Zymeworks Cash on Hand 2016-2022 | ZYME
Zymeworks cash on hand from 2016 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Zymeworks Annual Cash on Hand
(Millions of US $) |
| 2021 |
$253 |
| 2020 |
$426 |
| 2019 |
$299 |
| 2018 |
$200 |
| 2017 |
$88 |
| 2016 |
$40 |
| 2015 |
$15 |
Zymeworks Quarterly Cash on Hand
(Millions of US $) |
| 2022-06-30 |
$242 |
| 2022-03-31 |
$301 |
| 2021-12-31 |
$253 |
| 2021-09-30 |
$308 |
| 2021-06-30 |
$360 |
| 2021-03-31 |
$411 |
| 2020-12-31 |
$426 |
| 2020-09-30 |
$472 |
| 2020-06-30 |
$437 |
| 2020-03-31 |
$488 |
| 2019-12-31 |
$299 |
| 2019-09-30 |
$335 |
| 2019-06-30 |
$356 |
| 2019-03-31 |
$180 |
| 2018-12-31 |
$200 |
| 2018-09-30 |
$150 |
| 2018-06-30 |
$166 |
| 2018-03-31 |
$70 |
| 2017-12-31 |
$88 |
| 2017-09-30 |
$49 |
| 2017-06-30 |
$62 |
| 2017-03-31 |
$27 |
| 2016-12-31 |
$40 |
| 2016-09-30 |
|
| 2016-06-30 |
|
| 2016-03-31 |
|
| 2015-12-31 |
$15 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.570B |
$0.412B |
|
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
|
